MDxHealth, Inc. Announces Positive Medical Policy For ConfirmMDx Issued By One Of The Top Five Health Insurers In The US
IRVINE, CA, and HERSTAL, BELGIUM – August 10, 2016 – MDxHealth SA (Euronext: MDXH.BR) announced a positive medical policy decision for ConfirmMDx® for Prostate Cancer test issued by Cigna, one of the top five largest health insurers in the US.
This positive medical policy decision follows the recently updated NCCN Guidelines for Prostate Cancer Early Detection Version 2.2016 and adds to the expanding list of payers that have adopted positive medical policy on ConfirmMDx for Prostate Cancer.
"Cigna's positive medical policy is another major milestone for our ConfirmMDx for Prostate Cancer test," stated Dr. Jan Groen, CEO of MDxHealth. “We are seeing increasing recognition and adoption of ConfirmMDx to improve patient outcomes and manage rising healthcare costs among the urology and managed care communities.”
About ConfirmMDx for Prostate Cancer
ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer which addresses false negative biopsy concerns. It is the only molecular diagnostic test that provides a very high negative predictive value (NPV) of 96% for clinically significant prostate cancers, and 90% NPV for all prostate cancers, as well as prostate mapping of the test results to help guide repeat biopsies. Each year, more than 1 million American men undergo an invasive prostate biopsy with a negative result, however approximately 30% of those men actually have prostate cancer. The current standard of care for prostate biopsy procedures samples less than 1% of the prostate, leaving men at risk for undetected cancer and leading to a high rate of repeat biopsies, even on cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. To date nearly 2,800 urologists have ordered ConfirmMDx on more than 45,000 patients. ConfirmMDx has qualified for Medicare, Medicare Advantage and many private reimbursement plans.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
This positive medical policy decision follows the recently updated NCCN Guidelines for Prostate Cancer Early Detection Version 2.2016 and adds to the expanding list of payers that have adopted positive medical policy on ConfirmMDx for Prostate Cancer.
"Cigna's positive medical policy is another major milestone for our ConfirmMDx for Prostate Cancer test," stated Dr. Jan Groen, CEO of MDxHealth. “We are seeing increasing recognition and adoption of ConfirmMDx to improve patient outcomes and manage rising healthcare costs among the urology and managed care communities.”
About ConfirmMDx for Prostate Cancer
ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer which addresses false negative biopsy concerns. It is the only molecular diagnostic test that provides a very high negative predictive value (NPV) of 96% for clinically significant prostate cancers, and 90% NPV for all prostate cancers, as well as prostate mapping of the test results to help guide repeat biopsies. Each year, more than 1 million American men undergo an invasive prostate biopsy with a negative result, however approximately 30% of those men actually have prostate cancer. The current standard of care for prostate biopsy procedures samples less than 1% of the prostate, leaving men at risk for undetected cancer and leading to a high rate of repeat biopsies, even on cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. To date nearly 2,800 urologists have ordered ConfirmMDx on more than 45,000 patients. ConfirmMDx has qualified for Medicare, Medicare Advantage and many private reimbursement plans.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.